Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT04647890
Registration number
NCT04647890
Ethics application status
Date submitted
16/11/2020
Date registered
1/12/2020
Date last updated
20/12/2023
Titles & IDs
Public title
Effects of FT011 in Systemic Sclerosis
Query!
Scientific title
A Phase II, Randomised, Double Blind, Placebo-controlled Study of the Pharmacokinetics, Pharmacodynamic Effects, and Safety, of Oral FT011 in Participants With Diffuse Systemic Sclerosis
Query!
Secondary ID [1]
0
0
CER-FT011-SSc01
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Scleroderma, Systemic
0
0
Query!
Scleroderma, Diffuse
0
0
Query!
Sclerosis, Systemic
0
0
Query!
Condition category
Condition code
Inflammatory and Immune System
0
0
0
0
Query!
Autoimmune diseases
Query!
Skin
0
0
0
0
Query!
Dermatological conditions
Query!
Skin
0
0
0
0
Query!
Other skin conditions
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - FT011
Treatment: Drugs - FT011
Treatment: Drugs - Placebo
Experimental: FT011 200mg - 200mg once daily for 12 weeks
Experimental: FT011 400mg - 400mg once daily for 12 weeks
Placebo Comparator: Placebo - Placebo once daily for 12 weeks
Treatment: Drugs: FT011
Two x 100mg capsules once daily for 12 weeks
Treatment: Drugs: FT011
Two x 200mg capsules once daily for 12 weeks
Treatment: Drugs: Placebo
Two placebo capsules once daily for 12 weeks
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
FT011 Levels in Plasma
Query!
Assessment method [1]
0
0
Measurement of maximum concentration (cmax) of FT011. First dose Cmax and last dose Cmax for each participant were averaged together to calculate a single mean Cmax for each treatment arm
Query!
Timepoint [1]
0
0
Mean of cmax post first dose and cmax post last dose
Query!
Primary outcome [2]
0
0
FT011 Levels in Plasma
Query!
Assessment method [2]
0
0
Measurement of time to cmax (tmax). First dose tmax and last dose tmax for each participant were averaged together to calculate a single mean tmax for each treatment arm
Query!
Timepoint [2]
0
0
Mean of time to cmax post first dose and time to cmax post last dose
Query!
Primary outcome [3]
0
0
FT011 Levels in Plasma
Query!
Assessment method [3]
0
0
Measurement of area under the concentration time curve (AUC). First dose AUC and last dose AUC for each participant were averaged together to calculate a single mean AUC for each active arm
Query!
Timepoint [3]
0
0
Mean of AUC hours post first dose and AUC hours post last dose
Query!
Secondary outcome [1]
0
0
Number of Participants With Treatment-Emergent Adverse Events (TEAEs) From Baseline to End of Study
Query!
Assessment method [1]
0
0
TEAEs per arm during study treatment and follow up periods
Query!
Timepoint [1]
0
0
Baseline to Week 16
Query!
Secondary outcome [2]
0
0
mRSS Change From Baseline
Query!
Assessment method [2]
0
0
The mRSS is a validated physical evaluation of patient's skin thickness rated by clinical palpation using a 0-3 scale (0 = normal skin; 1 = mild thickness; 2 = moderate thickness; 3 = severe thickness with inability to pinch the skin into a fold) for each of 17 surface anatomic areas of the body: face, anterior chest, abdomen, and, with right and left sides of the body separately evaluated, the fingers, forearms, upper arms, thighs, lower legs, dorsum of hands and feet. Individual values are summed and defined as the total skin score. Total score is 0 to 51 with higher scores indicating worse symptomology
Query!
Timepoint [2]
0
0
End of treatment (week 12)
Query!
Secondary outcome [3]
0
0
%FVC Change From Baseline
Query!
Assessment method [3]
0
0
Percent predicted FVC is calculated using equations incorporating age, gender, and race. It is calculated as (FVC Observed / FVC predicted) x 100, where FVC predicted is calculated relative to a reference population
Query!
Timepoint [3]
0
0
End of treatment (Week 12)
Query!
Secondary outcome [4]
0
0
Physician Global Assessment Change From Baseline
Query!
Assessment method [4]
0
0
The physician's assessment of the patient's SSc status will be scored on a 100-mm horizontal VAS, ranging from 0 on the extreme left end of the scale indicating "no disease activity" (symptom free), and 100 on the extreme right end indicating "worst imaginable disease activity".
Query!
Timepoint [4]
0
0
End of treatment (Week 12)
Query!
Secondary outcome [5]
0
0
Patient Global Assessment Change From Baseline
Query!
Assessment method [5]
0
0
The Patient's Global Assessment represents the patient's overall assessment of current SSc status on a 100-mm horizontal VAS, ranging from 0 on the extreme left end of the scale indicating "no disease activity" (symptom free), and 100 on the extreme right end indicating "worst imaginable disease activity".
Query!
Timepoint [5]
0
0
End of treatment (Week 12)
Query!
Secondary outcome [6]
0
0
Scleroderma HAQ-DI Change From Baseline
Query!
Assessment method [6]
0
0
The HAQ-DI consists of 20 questions referring to eight component sets consisting of dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities. Each item is scored from 0 to 3. The eight scores of the eight sections are summed and divided by 8. The total score indicates the patient's self-assessed level of disability - higher scores indicate worse symptomology. A negative change from baseline indicates improvement. The Scleroderma HAQ (SHAQ) includes an additional five scleroderma-specific visual analogue scales (VAS), addressing overall disease activity, Raynaud's phenomenon, finger ulcers, breathing, and intestinal problems. A composite VAS score is not created nor are the individual VAS scores incorporated into the HAQ DI score.
Query!
Timepoint [6]
0
0
End of treatment (Week 12)
Query!
Secondary outcome [7]
0
0
Combined Response Index in Diffuse Cutaneous Systemic Sclerosis (CRISS) at Week 12
Query!
Assessment method [7]
0
0
CRISS components include modified Rodnan skin score (mRSS), forced vital capacity percent predicted (%FVC), Physician Global Assessment, Patient Global Assessment, and Health Assessment Questionnaire Disability-Index (HAQ-DI). The exponential algorithm determines the predicted probability of improvement from baseline, incorporating change in these 5 components. The outcome is a continuous variable between 0.0 and 1.0 (0 - 100%). A higher score indicates greater improvement
Query!
Timepoint [7]
0
0
Week 12
Query!
Secondary outcome [8]
0
0
Scleroderma Clinical Trial Consortium Damage Index (SCTC-DI) Change From Baseline
Query!
Assessment method [8]
0
0
The SCTC-DI is a 23-item composite damage index to quantify organ damage in systemic sclerosis (0-55 scale; moderate damage >5, severe damage>12)
Query!
Timepoint [8]
0
0
End of treatment (Week 12)
Query!
Secondary outcome [9]
0
0
5-D Itch Scale Change From Baseline
Query!
Assessment method [9]
0
0
The 5-D itch scale is a 23-item validated instrument used to measure five domains of chronic itch: duration, degree, direction, disability, and distribution. Scores range from 5 to 25, with higher scores indicating a higher severity of chronic itch.
Query!
Timepoint [9]
0
0
End of treatment (Week 12)
Query!
Eligibility
Key inclusion criteria
1. Provide written informed consent prior to any study procedures and who agree to adhere
to all protocol requirements.
2. Aged 18 to 75 years inclusive at the time of consent.
3. Have a classification of systemic sclerosis, as defined by American College of
Rheumatology (ACR) and European League Against Rheumatism (EULAR) criteria with
disease duration =10 years from first non-Raynaud phenomenon manifestation.
4. Have a diagnosis of diffuse cutaneous SSc defined as systemic sclerosis with skin
thickening on the upper arms proximal to the elbows, on the upper legs proximal to the
knees, or on the trunk.
5. Have skin thickening in a body area suitable for repeat biopsy.
6. Have a mRSS at Screening of =15 to =40.
7. FVC =50% of predicted at Screening.
8. If on azathioprine, mycophenolate mofetil, or hydroxychloroquine, have been on a
stable dose for at least 2 months prior to baseline.
9. Women of childbearing potential (WOCPB) and males with partners of child-bearing
potential must agree to use highly effective contraception (a failure rate of <1%),
for the duration of the study and until three months after their last dose of IMP.
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
75
Years
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
1. Pregnant or breast-feeding, or plan to become pregnant during the study.
2. Have received any IMP within 30 days or 5 half-lives prior to randomisation (4 months
if the previous drug was a new chemical entity), whichever is longer.
3. Have known or suspected contraindications to the IMP.
4. Have severe or unstable SSc or end-stage organ involvement as evidenced by:
1. On an organ transplantation list or has received an organ transplant including
autologous stem cell transplant.
2. Renal crisis within 1 year prior to Baseline.
5. Interstitial lung disease or pulmonary hypertension requiring constant oxygen therapy.
This excludes oxygen used to aid sleep or exercise.
6. Gastrointestinal dysmotility requiring total parenteral nutrition or requiring
hospitalisation within the 6 months prior to Baseline.
7. Concomitant inflammatory myositis, rheumatoid arthritis, or systemic lupus
erythematosus when definite classification criteria for those diseases are met (Bohan
and Peter criteria for polymyositis and dermatomyositis)
8. SSc-like illnesses related to exposures or ingestions
9. The use of the following drugs within the specified periods:
1. Methotrexate in the 2 weeks prior to Day 1
2. Other anti-fibrotic agents including D-penicillamine or tyrosine kinase
inhibitors (nilotinib, imatinib, dasatinib) in the month prior to Screening.
3. Biologic drugs such as tumour necrosing factor (TNF) inhibitors, tocilizumab, or
Janus kinase (JAK) inhibitors, in the 3 months prior to Screening.
4. Rituximab in the 6 months prior to Screening.
5. Cyclophosphamide oral or IV in the 3 months prior to Screening.
6. Oral prednisolone >10 mg per day or IV steroids in the month prior to Screening.
10. Have any malignancy not considered cured (except basal cell or squamous cell carcinoma
of the skin, or carcinoma in situ of the cervix); a subject is considered cured if
there has been no evidence of cancer recurrence for the 6 years prior to
randomisation.
11. Have aspartate transaminase (AST), alanine transaminase (ALT), gamma-glutamyl
transferase (GGT), lactate dehydrogenase (LDH), or bilirubin values above the upper
limit of normal (ULN) at Screening or Baseline, or evidence of hepatic disease as
determined by any one of the following: history of hepatic encephalopathy, history of
oesophageal varices, or history of portacaval shunt.
12. Estimated glomerular filtration rate (eGFR) <60mL/min, urinary albumin/creatinine
ratio >30mg/g.
13. Haemoglobin < 80 g/L, platelets < 90 x 109/L, or neutrophil count < 1.4 x 109/L
14. Other than SSc, have any other medical condition or significant co-morbidities,
clinically relevant social or psychiatric conditions, or any finding during Screening,
which in the investigator's opinion may put the subject at risk or interfere with the
study objectives.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 2
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
19/07/2021
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
16/11/2022
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
30
Query!
Recruitment in Australia
Recruitment state(s)
SA,VIC
Query!
Recruitment hospital [1]
0
0
Royal Adelaide Hospital - Adelaide
Query!
Recruitment hospital [2]
0
0
St Vincent's Hospital Melbourne - Fitzroy
Query!
Recruitment postcode(s) [1]
0
0
5000 - Adelaide
Query!
Recruitment postcode(s) [2]
0
0
3065 - Fitzroy
Query!
Recruitment outside Australia
Country [1]
0
0
Netherlands
Query!
State/province [1]
0
0
Nijmegen
Query!
Country [2]
0
0
Poland
Query!
State/province [2]
0
0
Bydgoszcz
Query!
Country [3]
0
0
Poland
Query!
State/province [3]
0
0
Kraków
Query!
Country [4]
0
0
Poland
Query!
State/province [4]
0
0
Malbork
Query!
Country [5]
0
0
Poland
Query!
State/province [5]
0
0
Warsaw
Query!
Country [6]
0
0
Spain
Query!
State/province [6]
0
0
Barcelona
Query!
Country [7]
0
0
Ukraine
Query!
State/province [7]
0
0
Kyiv
Query!
Country [8]
0
0
Ukraine
Query!
State/province [8]
0
0
Poltava
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
Certa Therapeutics
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
FT011 is an anti-fibrotic drug that is being tested as a treatment for scleroderma. This
study is being conducted to see what the body does to the drug (pharmacokinetics), and what
the drug does to the body (pharmacodynamics).
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT04647890
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Darren Kelly, PhD
Query!
Address
0
0
Certa Therapeutics Pty Ltd
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT04647890
Download to PDF